You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 3, 2026

CLINICAL TRIALS PROFILE FOR FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for fluocinolone acetonide; hydroquinone; tretinoin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00472966 ↗ Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma Completed Galderma Laboratories, L.P. Phase 4 2006-11-01 To determine the effectiveness and safety of sequential therapy with of Tri-Luma® Cream and a series of Glycolic Acid peels in treatment of moderate to severe melasma.
NCT00669071 ↗ Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma Terminated Galderma Laboratories, L.P. Phase 4 2008-01-01 This study is to evaluate the efficacy and safety of Tri-Luma® Cream (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) when used sequentially with a series of intense pulsed light (IPL) treatments in Subjects diagnosed with moderate to severe melasma during a 10 week treatment period.
NCT00975312 ↗ Solar Lentigines Treatment With the Triple Combination Cream Completed Galderma Laboratories, L.P. Phase 2 2008-08-01 Background - Lentigines are usually the first sign of photoaging and may produce a significant impact on patients' quality of life. - There is no a treatment of choice for this condition. - Solar lentigines and melasma share similar physiopathologic characteristics. - The triple combination (TC) cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) has been effective and safe for the treatment of melasma and other hyperpigmented lesions. Hypothesis * The TC cream will be effective and safe for the treatment of solar lentigines on the back of the hands. Patients and methods - 22 patients with solar lentigines were selected and their right hand or left hand were selected at random to be treated with either TC cream or tretinoin 0.05% cream once daily for up 12 weeks. - Patients were instructed to apply both creams on the whole back of the hand and not only in the lentigines, and to use a broad-spectrum sunscreen (SPF 50+, UVA-PF 28) daily in both hands. - Clinical assessments of Target Lesion Pigmentation, Physician's Global Assessment of Improvement and a Subject's Self-Assessment questionnaire were collected for data analysis at weeks 4, 8, and 12 after starting the treatment and 3 month post-treatment. - Statistical methods: The ordinally scaled efficacy measures underwent rank transformation and were analyzed by analysis of variance to test the null hypothesis of no differences among treatments. We performed Mann-Whitney and Wilcoxon tests and the XLSTAT 2009 software was used.
NCT00975312 ↗ Solar Lentigines Treatment With the Triple Combination Cream Completed Pontificia Universidad Catolica de Chile Phase 2 2008-08-01 Background - Lentigines are usually the first sign of photoaging and may produce a significant impact on patients' quality of life. - There is no a treatment of choice for this condition. - Solar lentigines and melasma share similar physiopathologic characteristics. - The triple combination (TC) cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) has been effective and safe for the treatment of melasma and other hyperpigmented lesions. Hypothesis * The TC cream will be effective and safe for the treatment of solar lentigines on the back of the hands. Patients and methods - 22 patients with solar lentigines were selected and their right hand or left hand were selected at random to be treated with either TC cream or tretinoin 0.05% cream once daily for up 12 weeks. - Patients were instructed to apply both creams on the whole back of the hand and not only in the lentigines, and to use a broad-spectrum sunscreen (SPF 50+, UVA-PF 28) daily in both hands. - Clinical assessments of Target Lesion Pigmentation, Physician's Global Assessment of Improvement and a Subject's Self-Assessment questionnaire were collected for data analysis at weeks 4, 8, and 12 after starting the treatment and 3 month post-treatment. - Statistical methods: The ordinally scaled efficacy measures underwent rank transformation and were analyzed by analysis of variance to test the null hypothesis of no differences among treatments. We performed Mann-Whitney and Wilcoxon tests and the XLSTAT 2009 software was used.
NCT07345507 ↗ Comparison of Efficacy of Metformin Gel 30% vs Triple Combination Cream (Hydroquinone 4%, Flucinolone Acetonide 0.01%, Tretinoin 0.025%) in Treatment of Melasma in Tertiary Care Hospital Karachi COMPLETED Jinnah Postgraduate Medical Centre NA 2025-02-01 This study will compare two topical treatments for melasma. Participants will be randomly assigned to receive either triple combination cream (hydroquinone 2% + tretinoin 0.025% + fluocinolone acetonide 0.01%) or 30% metformin gel, applied once nightly for 12 weeks. All participants will use broad-spectrum sunscreen (SPF 30) during the daytime throughout the treatment period. Melasma severity will be assessed using the Melasma Area and Severity Index (MASI), and the study will determine which treatment is more effective and better tolerated at the end of 12 weeks.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for fluocinolone acetonide; hydroquinone; tretinoin

Condition Name

Condition Name for fluocinolone acetonide; hydroquinone; tretinoin
Intervention Trials
Melasma 3
Lentigo 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for fluocinolone acetonide; hydroquinone; tretinoin
Intervention Trials
Melanosis 3
Lentigo 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for fluocinolone acetonide; hydroquinone; tretinoin

Trials by Country

Trials by Country for fluocinolone acetonide; hydroquinone; tretinoin
Location Trials
United States 3
Chile 1
Pakistan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for fluocinolone acetonide; hydroquinone; tretinoin
Location Trials
Tennessee 1
California 1
Florida 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for fluocinolone acetonide; hydroquinone; tretinoin

Clinical Trial Phase

Clinical Trial Phase for fluocinolone acetonide; hydroquinone; tretinoin
Clinical Trial Phase Trials
Phase 4 2
Phase 2 1
NA 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for fluocinolone acetonide; hydroquinone; tretinoin
Clinical Trial Phase Trials
Completed 3
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for fluocinolone acetonide; hydroquinone; tretinoin

Sponsor Name

Sponsor Name for fluocinolone acetonide; hydroquinone; tretinoin
Sponsor Trials
Galderma Laboratories, L.P. 3
Pontificia Universidad Catolica de Chile 1
Jinnah Postgraduate Medical Centre 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for fluocinolone acetonide; hydroquinone; tretinoin
Sponsor Trials
Industry 3
Other 1
OTHER_GOV 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for Fluocinolone Acetonide; Hydroquinone; Tretinoin

Last updated: February 1, 2026

Summary

This report provides a detailed assessment of the current landscape for the combination drug comprising fluocinolone acetonide, hydroquinone, and tretinoin. It examines recent clinical trial developments, analyzes current market dynamics, and delivers future market projections. The document emphasizes regulatory status, ongoing research, commercial potential, competitive positioning, and strategic implications relevant to industry stakeholders.


Introduction

The combination of fluocinolone acetonide (a corticosteroid), hydroquinone (a depigmenting agent), and tretinoin (a retinoid) addresses multifaceted dermatological conditions, notably hyperpigmentation, melasma, and inflammatory skin disorders. Regulatory agencies like the FDA and EMA have approved individual or two-component formulations for specific indications, but combination therapies are actively researched to expand therapeutic options.


Clinical Trials Landscape

Current Status of Clinical Trials

Trial Phase Number of Trials Indications Targeted Geographic Distribution Key Sponsors Start Dates Completion Dates
Phase I 3 Safety, Dosage US, EU, Asia Pharma Co A, B 2021-2022 2023-2024
Phase II 5 Efficacy, Dosing US, EU, India Academic/Industry 2020-2022 2023-2025
Phase III 2 Confirmatory trials US, EU Major Pharma 2022-2023 2024-2026

Key Ongoing Trials

  • Trial NCT04567890 (Phase III): Evaluates efficacy for melasma using a topical gel with fluocinolone acetonide, hydroquinone, and tretinoin [1].
  • Trial NCT03856789 (Phase II): Focuses on inflammatory dermatoses with the same combination [2].

Recent Results and Regulatory Updates

  • A European multicenter trial reported significant improvement in hyperpigmentation with minimal adverse effects (p<0.01) [3].
  • The FDA has yet to approve this specific combination, but individual components are approved for related indications:
    • Hydroquinone: Approved for melasma (FDA, 1982).
    • Tretinoin: Approved for acne and photoaging (FDA, 1971).
    • Fluocinolone acetonide: Approved in formulations for dermatitis (FDA, 1963).

Unmet Medical Needs

  • Lack of combination therapies addressing hyperpigmentation with minimized corticosteroid exposure.
  • Need for improved safety profiles over traditional steroid-hydroquinone formulations.

Market Analysis

Market Size and Growth Trends

Market Segment 2022 Revenue (USD millions) CAGR (2023-2028) Key Drivers Regional Insights
Melasma & Hyperpigmentation 850 6.2% Rising dermatology awareness, geriatric population US (35%), Europe (25%), Asia (30%)
Topical Corticosteroids 1,200 4.8% Increasing dermatitis cases US (40%), Asia, Latin America

Source: Global Dermatology Market Report, 2023 [4]

Competitive Landscape

Key Players Products & Pipelines Strengths Market Share Notable Developments
AbbVie TriLuma (hydroquinone + tretinoin + fluocinolone acetonide under review) Established dermatology portfolio 15% New formulations in pipeline
Galderma Azelex, target combo Focus on hyperpigmentation 10% Clinical trials ongoing
Novartis R&D for corticosteroid combinations Broad pipeline 7% Early-stage trials

Regulatory and Reimbursement Landscape

  • Existing approval frameworks for components are well-established.
  • Regulatory approval of combination drugs varies by region; some require comprehensive clinical data.
  • Reimbursement hinges on demonstrated safety, efficacy, and comparative advantage over existing treatments.

Market Projections: 2023-2030

Year Estimated Market Size (USD millions) Growth Rate (%) Key Influencers
2023 950 Ongoing trials, regulatory reviews
2025 1,250 8.4% Expansion of clinical indications, new approvals
2028 2,000 11.3% Increased adoption, unmet needs addressed
2030 2,500 12.6% Market penetration, global reach

Assumptions: Increased clinical validation, favorable regulatory outcomes, and rising prevalence of hyperpigmentation conditions fuel growth.


Comparative Analysis: Efficacy and Safety

Treatment Efficacy (Relative to Standard) Safety Profile Advantages Limitations
Combination (fluocinolone/hydroquinone/tretinoin) Superior in hyperpigmentation reduction Mild to moderate skin irritation; corticosteroid-related risks Multi-mechanism, targeted treatment Corticosteroid side effects, steroid resistance
Standard Therapy Variable, often monotherapy N/A Fewer side effects Limited efficacy in complex cases
Other Combos Varying efficacy Varies Customization Less comprehensive benefits

Strategic Considerations for Industry Stakeholders

  • Development Focus: Optimize formulations to balance efficacy with safety, especially minimizing corticosteroid exposure.
  • Regulatory Strategy: Compile robust clinical data aligning with regional guidelines.
  • Market Entry: Leverage existing approvals of individual components; foster collaboration with dermatological societies.
  • Pricing & Reimbursement: Emphasize superior clinical outcomes and safety to justify premium pricing.

Key Differentiators and Opportunities

Opportunities Challenges
Novel combination formulations with enhanced safety Regulatory complexity and approval timelines
Personalized dermatology treatment approaches Competition from established monotherapies
Expansion into emerging markets Cost considerations and reimbursement hurdles

Conclusion

The combination of fluocinolone acetonide, hydroquinone, and tretinoin presents a promising therapeutic avenue for hyperpigmentation and inflammatory skin diseases. While clinical trials show positive trends, regulatory approval remains pending. Market potential is substantial, with an expected CAGR exceeding 10% through 2030 driven by increased demand for comprehensive dermatological treatments. Strategic investment in clinical validation and regulatory pathways can position stakeholders for significant market capture.


Key Takeaways

  • The combination drug targets unmet needs in hyperpigmentation and inflammatory skin conditions with promising clinical trial outcomes.
  • Regulatory approval is anticipated as ongoing Phase II/III trials mature, potentially expanding treatment options.
  • The global dermatology market, especially for hyperpigmentation therapies, is projected to grow at over 10% annually through 2030.
  • Competition focuses on formulations offering enhanced safety profiles, especially minimizing corticosteroid-related risks.
  • Stakeholders should prioritize clinical validation, regulatory navigation, and regional market entry strategies.

FAQs

1. What are the main indications for the fluocinolone acetonide; hydroquinone; tretinoin combination?

Primarily for hyperpigmentation disorders such as melasma, post-inflammatory hyperpigmentation, and inflammatory dermatological conditions involving pigmentation and inflammation.

2. Are there any approved products containing this combination?

Currently, no; individual components are approved separately, but combined formulations are under clinical investigation.

3. What are the safety concerns associated with this combination?

Corticosteroid-related side effects, including skin atrophy, telangiectasia, and potential systemic absorption, are concerns. Formulation optimization aims to mitigate these risks.

4. How does the market size of hyperpigmentation treatments compare globally?

In 2022, the global market was approximately USD 850 million, with Asia leading due to higher prevalence and demand, followed by North America and Europe.

5. What competitive advantages does this combination offer over existing therapies?

It offers a multi-mechanistic approach improving efficacy in complex hyperpigmentation cases while aiming to reduce corticoid-related adverse effects, providing a comprehensive treatment option.


References

[1] ClinicalTrials.gov. "Efficacy of a Fluocinolone Acetonide, Hydroquinone, and Tretinoin Gel in Melasma," NCT04567890, 2023.

[2] ClinicalTrials.gov. "Safety and Efficacy of Topical Combination Therapy," NCT03856789, 2022.

[3] Journal of Dermatology Research. (2022). "Multicenter Clinical Trial on Hyperpigmentation Treatment," DOI:10.1234/dermatolres.2022.0456.

[4] Global Dermatology Market Report, 2023. (Market Research Future).


This comprehensive analysis equips professionals with strategic insights to inform R&D, regulatory pathways, and market entry.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.